Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neuroaid II for Post-Stroke Cognitive Impairment (NEURITES)
NCT01847924Phase 2Completed
- Sponsor
- National University Hospital
- Start
- Mar 2013
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of mlc901 in vascular cognitive impairment (VCI), sponsored by National University Hospital. Primary endpoint: Verbal Fluency at 24 weeks. Started Mar 2013; status: completed.
02
Drugs
mlc901
03
Conditions
vascular cognitive impairment (VCI)
Beyond the preview
Go deeper on NCT01847924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01847924.